The study, sponsored by Centinel Spine, will include patients ages 18 to 69 who have a diagnosis of radiculopathy or myelopathy with radiculopathy, according to a June 1 news release. About 390 patients will be enrolled in the trial.
Centinel Spine’s Prodisc C and Prodisc C Vivo will be compared with Zimmer Biomet’s Mobi C disc in the study.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
